172 related articles for article (PubMed ID: 31639703)
1. Evaluation of CisBio ELISA for Chromogranin A Measurement.
Lim M; Erdman P; Cho S; Mathew A; Fleisher M; Thoren KL
J Appl Lab Med; 2019 Jul; 4(1):11-18. PubMed ID: 31639703
[TBL] [Abstract][Full Text] [Related]
2. True Chromogranin A concentrations in plasma from patients with small intestinal neuroendocrine tumours.
Rehfeld JF; Broedbaek K; Goetze JP; Knigge U; Hilsted LM
Scand J Gastroenterol; 2020 May; 55(5):565-573. PubMed ID: 32352887
[No Abstract] [Full Text] [Related]
3. Comparison of chromogranin A (CgA) levels in serum and plasma (EDTA2K) and the respective reference ranges in healthy males.
Glinicki P; Jeske W; Kapuścińska R; Zgliczyński W
Endokrynol Pol; 2015; 66(1):53-6. PubMed ID: 25754282
[TBL] [Abstract][Full Text] [Related]
4. The differences in chromogranin A (CgA) concentrations measured in serum and in plasma by IRMA and ELISA methods.
Glinicki P; Kapuścińska R; Jeske W
Endokrynol Pol; 2010; 61(4):346-50. PubMed ID: 20806177
[TBL] [Abstract][Full Text] [Related]
5. Chromogranin A is a reliable serum diagnostic biomarker for pancreatic neuroendocrine tumors but not for insulinomas.
Qiao XW; Qiu L; Chen YJ; Meng CT; Sun Z; Bai CM; Zhao DC; Zhang TP; Zhao YP; Song YL; Wang YH; Chen J; Lu CM
BMC Endocr Disord; 2014 Aug; 14():64. PubMed ID: 25099181
[TBL] [Abstract][Full Text] [Related]
6. Routine measurement of plasma chromogranin B has limited clinical utility in the management of patients with neuroendocrine tumours.
Monaghan PJ; Lamarca A; Valle JW; Hubner RA; Mansoor W; Trainer PJ; Darby D
Clin Endocrinol (Oxf); 2016 Mar; 84(3):348-52. PubMed ID: 26608723
[TBL] [Abstract][Full Text] [Related]
7. Use of Chromogranin A for Monitoring Patients With Pancreatic Neuroendocrine Neoplasms.
Yu F; Fu J; Zhang C; Wu W; Ai S; Yao X; Meng Q; Huang Y; Lu G; Wang F; Qu W
Pancreas; 2021 Jul; 50(6):882-889. PubMed ID: 34347728
[TBL] [Abstract][Full Text] [Related]
8. Comparison of two chromogranin A assays and investigation of nonlinear specimens.
Erickson JA; Chiang FI; Walker CM; Genzen JR; Doyle K
Pract Lab Med; 2022 Nov; 32():e00299. PubMed ID: 36035319
[TBL] [Abstract][Full Text] [Related]
9. Serum chromogranin A is a useful marker for Japanese patients with pancreatic neuroendocrine tumors.
Hijioka M; Ito T; Igarashi H; Fujimori N; Lee L; Nakamura T; Jensen RT; Takayanagi R
Cancer Sci; 2014 Nov; 105(11):1464-71. PubMed ID: 25220535
[TBL] [Abstract][Full Text] [Related]
10. Automated two-site immunofluorescent assay for the measurement of serum chromogranin A.
Popovici T; Moreira B; Schlageter MH; Bories PN
Clin Biochem; 2014 Jan; 47(1-2):87-91. PubMed ID: 24201067
[TBL] [Abstract][Full Text] [Related]
11. Serum chromogranin A levels for the diagnosis and follow-up of well-differentiated non-functioning neuroendocrine tumors.
Cheng Y; Sun Z; Bai C; Yan X; Qin R; Meng C; Ying H
Tumour Biol; 2016 Mar; 37(3):2863-9. PubMed ID: 26408184
[TBL] [Abstract][Full Text] [Related]
12. A score derived from routine biochemical parameters increases the diagnostic accuracy of chromogranin A in detecting patients with neuroendocrine neoplasms.
Kruljac I; Vurnek I; Maasberg S; Kust D; Blaslov K; Ladika Davidović B; Štefanović M; Demirović A; Bišćanin A; Filipović-Čugura J; Marić Brozić J; Pape UF; Vrkljan M
Endocrine; 2018 Jun; 60(3):395-406. PubMed ID: 29633144
[TBL] [Abstract][Full Text] [Related]
13. Prospective Study of Chromogranin A as a Predictor of Progression in Patients with Pancreatic, Small-Intestinal, and Unknown Primary Neuroendocrine Tumors.
Dam G; Grønbæk H; Sorbye H; Thiis Evensen E; Paulsson B; Sundin A; Jensen C; Ebbesen D; Knigge U; Tiensuu Janson E
Neuroendocrinology; 2020; 110(3-4):217-224. PubMed ID: 31578011
[TBL] [Abstract][Full Text] [Related]
14. Comparison between two methods in the determination of circulating chromogranin A in neuroendocrine tumors (NETs): results of a prospective multicenter observational study.
Leon A; Torta M; Dittadi R; degli Uberti E; Ambrosio MR; Delle Fave G; De Braud F; Tomassetti P; Gion M; Dogliotti L
Int J Biol Markers; 2005; 20(3):156-68. PubMed ID: 16240843
[TBL] [Abstract][Full Text] [Related]
15. Accuracy and clinical correlates of two different methods for chromogranin A assay in neuroendocrine tumors.
Ferrari L; Seregni E; Lucignani G; Bajetta E; Martinetti A; Aliberti G; Pallotti F; Procopio G; Della Torre S; Luksch R; Bombardieri E
Int J Biol Markers; 2004; 19(4):295-304. PubMed ID: 15646836
[TBL] [Abstract][Full Text] [Related]
16. Chromogranin A as a marker for diagnosis, treatment, and survival in patients with gastroenteropancreatic neuroendocrine neoplasm.
Wang YH; Yang QC; Lin Y; Xue L; Chen MH; Chen J
Medicine (Baltimore); 2014 Dec; 93(27):e247. PubMed ID: 25501094
[TBL] [Abstract][Full Text] [Related]
17. Chromogranin A predicts survival for resected pancreatic neuroendocrine tumors.
Shanahan MA; Salem A; Fisher A; Cho CS; Leverson G; Winslow ER; Weber SM
J Surg Res; 2016 Mar; 201(1):38-43. PubMed ID: 26850182
[TBL] [Abstract][Full Text] [Related]
18. The value of serum chromogranin A as a predictor of tumor burden, therapeutic response, and nomogram-based survival in well-moderate nonfunctional pancreatic neuroendocrine tumors with liver metastases.
Han X; Zhang C; Tang M; Xu X; Liu L; Ji Y; Pan B; Lou W
Eur J Gastroenterol Hepatol; 2015 May; 27(5):527-35. PubMed ID: 25822862
[TBL] [Abstract][Full Text] [Related]
19. [Chromogranin A (CgA) - characteristic of the currently available laboratory methods and conditions which can influence the results].
Glinicki P; Jeske W
Endokrynol Pol; 2009; 60(5):415-9. PubMed ID: 19885814
[TBL] [Abstract][Full Text] [Related]
20. Effect of Lanreotide Depot/Autogel on Urinary 5-Hydroxyindoleacetic Acid and Plasma Chromogranin A Biomarkers in Nonfunctional Metastatic Enteropancreatic Neuroendocrine Tumors.
Pavel ME; Phan AT; Wolin EM; Mirakhur B; Liyanage N; Pitman Lowenthal S; Fisher GA; Vinik AI;
Oncologist; 2019 Apr; 24(4):463-474. PubMed ID: 30355775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]